Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

医学 化疗 生物标志物 安慰剂 阶段(地层学) 癌症 内科学 肿瘤科 肺癌 病理 生物 生物化学 古生物学 替代医学
作者
Ying Cheng,Liang Han,Lin Wu,Jun Chen,Hongmei Sun,Guilan Wen,Yinghua Ji,Anastasia Zimina,Jianhua Shi,Zhijie Pan,Jinsheng Shi,Xicheng Wang,Fang Yang,Xinyi Yang,M. Chen,Shiqi Zhong,Qingyu Wang,Jing Li,Jiancheng Cheng,Ling Chen,Yongqiang Shan,Junwu Zhu
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 6390-6390 被引量:1
标识
DOI:10.1158/1538-7445.am2024-6390
摘要

Abstract Background First-line serplulimab plus chemotherapy (chemo) significantly improved OS compared with chemo alone for patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase 3 ASTRUM-005 study. In this exploratory biomarker analysis, we retrospectively evaluated the association of proteome signature, genetic mutations, and hematological indices with efficacy. Methods: Serum proteomics data were generated via Olink® Explore 3072 platform for 168 patients (training: 80; validation: 88). Genetic mutations were assessed by Med1CDxTM panel for 305 patients. Baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels were analyzed in all 585 patients. Clinical data cutoff date was June 13, 2022. Results: From Olink data, we generated a 15-protein signature. Results in the validation cohort are shown in the table below. Patients with upper signature score derived higher PFS (7.89 vs 4.17 mo, HR 0.37) and OS (17.18 vs 9.74 mo, HR 0.27) benefit from adding serplulimab, than those with lower signature score (PFS: 4.40 vs 4.34 mo, HR 0.68; OS: 9.05 vs 9.22 mo, HR 0.76). Patients with mutations in RB1 or NOTCH pathway had better tumor responses to the treatment of serplulimab-chemo (ORR: 80% and 86%, respectively) when compared to patients without mutations in RB1 or NOTCH pathway (ORR: 58% and 68%). Patients with NLR ≤4.6, PLR ≤338.3, and LDH ≤ upper limit of normal tended to have longer PFS and OS in both treatment groups; NLR and LDH were further proven to be independent prognostic biomarkers in multivariate regression (P = 0.002 and P <0.001, respectively). Conclusions: We found a 15-protein signature showing predictive power for serplulimab-chemo treatment; RB1 or NOTCH pathway mutations were enriched in serplulimab-chemo responders; baseline NLR and LDH were independent prognostic biomarkers for ES-SCLC. The above findings warrant further investigations. Serplulimab-chemo (n=48) Placebo-chemo (n=40) HR (95% CI) P Upper signature score, n 31 34 Median PFS (95% CI), months 7.89 (1.27, 10.74) 4.17 (2.96, 4.34) 0.37 (0.21, 0.66) <0.001 Median OS (95% CI), months 17.18 (11.01, NE) 9.74 (6.90, 12.65) 0.27 (0.15, 0.50) <0.001 Lower signature score, n 17 6 Median PFS (95% CI), months 4.40 (3.61, 5.75) 4.34 (2.66, NE) 0.68 (0.23, 2.02) 0.488 Median OS (95% CI), months 9.05 (6.67, 11.73) 9.22 (4.53, NE) 0.76 (0.29, 1.98) 0.570 Citation Format: Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Fang Yang, Xinyi Yang, Mengkai Chen, Shiqi Zhong, Qingyu Wang, Jing Li, Jiancheng Cheng, Chen Ling, Yongqiang Shan, Jun Zhu, The ASTRUM-005 Study Group. Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6390.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健的小迷弟应助N_N采纳,获得10
2秒前
苏航发布了新的文献求助10
3秒前
4秒前
风中无血发布了新的文献求助10
8秒前
昏睡的绍辉完成签到,获得积分10
10秒前
11秒前
搜集达人应助daxiong采纳,获得10
14秒前
量子星尘发布了新的文献求助10
15秒前
15秒前
乐乐应助哼哼唧唧采纳,获得10
17秒前
风中无血完成签到,获得积分10
18秒前
zeng发布了新的文献求助10
25秒前
27秒前
苏航完成签到,获得积分20
27秒前
29秒前
FashionBoy应助伪装的鱼采纳,获得10
29秒前
29秒前
daxiong发布了新的文献求助10
31秒前
阿Q完成签到,获得积分10
31秒前
33秒前
33秒前
nczpf2010发布了新的文献求助10
34秒前
yufanhui应助包容剑鬼采纳,获得10
36秒前
肉肉发布了新的文献求助20
36秒前
Li完成签到 ,获得积分10
37秒前
38秒前
乔乔兔发布了新的文献求助10
38秒前
哼哼唧唧发布了新的文献求助10
39秒前
Hello应助田田采纳,获得10
40秒前
喜悦松完成签到,获得积分10
41秒前
完美世界应助伪装的鱼采纳,获得10
41秒前
调皮初蝶发布了新的文献求助10
42秒前
43秒前
beituo完成签到,获得积分10
43秒前
43秒前
bkagyin应助从容的戎采纳,获得10
44秒前
轻松的亦寒应助辻辰采纳,获得20
45秒前
46秒前
一颗大树完成签到,获得积分10
46秒前
万能图书馆应助Clr采纳,获得30
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975378
求助须知:如何正确求助?哪些是违规求助? 3519775
关于积分的说明 11199621
捐赠科研通 3256067
什么是DOI,文献DOI怎么找? 1798124
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305